TABLE 1

Genetic control of susceptibility to AI4 T-cell–induced type 1 diabetes*

Experiment groupTransferred cellsRecipientsDiabeticP value
1NOD.Ragnull.AI4 splenocytesNOD76.9 (13)
NOR0 (11)<0.001
2NOD.Ragnull.AI4 splenocytesNOD60 (10)
NOD.Chr1NOR30 (10)>0.05
3NOD.Ragnull.AI4 splenocytesNOD57.1 (7)
NOD.Chr2NOR42.8 (7)>0.05
4NOD.Ragnull.AI4 splenocytesNOD70 (10)
NOD.Chr4NOR0 (10)<0.005
5NOD.Ragnull.AI4 splenocytesNOD75 (12)
NOD.CD4null0 (10)<0.005
6NOD.Ragnull.AI4 splenocytesNOD75 (8)
NOD.CD8null33.3 (9)>0.05
7NOD.Ragnull.AI4 splenocytesNOD61.5 (13)
NOD.IgHnull0 (13)<0.001
8NOD.Ragnull.AI4 splenocytesNOD60 (10)
NOD.IgHEL.IgHnull70 (10)>0.05
9Activated AI4 T-cellsNOD100 (3)
NOR100 (3)
10Activated AI4 T-cellsNOD100 (4)
NOD.Chr4NOR100 (5)
NOD.CD4null100 (5)
11Activated AI4 T-cellsNOD100 (5)
NOD.IgHnull100 (5)
  • Data are percent (n).

  • *

    * NOD.Ragnull.AI4 splenocytes or in vitro–activated AI4 T-cells were transferred into 600R irradiated female recipients. Type 1 diabetes was monitored for a period of 2 weeks. Mice within each experimental group received the same preparation of AI4 T-cells.

  • Statistical analysis by χ2 test (vs. NOD recipients in the same experimental group).